Document:

EX-10.13

 Exhibit 10.13 

May     , 2016 
 Richard D. Katz, M.D.,
M.B.A 
 209 Sierra Drive 
 Chapel Hill, NC 27514 

Dear Rich, 
 It is my pleasure to extend the
following offer of employment to you on behalf of Viamet Pharmaceuticals Corp. (the “Company”) effective upon its conversion from Viamet Pharmaceuticals Holdings, LLC to a Delaware Corporation. The following is offered as part of your
compensation package: 
  

			
	Title:	  	Chief Financial Officer
		
	Base Salary:	  	As determined by the Compensation Committee of the Board of Directors from time to time

 You will be eligible to receive an annual cash bonus as determined by the Company’s Board of Directors in
accordance with the Company’s performance-based bonus program. 
 Your employment with the Company is for no specified period and
constitutes “at-will” employment in that it can be terminated with or without cause, and with or without notice, at any time, at the option of either the Company or yourself, except as otherwise provided by law. The terms of this offer
letter, therefore, do not and are not intended to create either an express and/or implied contract of employment with the Company. Similarly, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any
compensation or grant you any benefit beyond the end of your employment with the Company. 
 This letter sets forth the terms of your
employment with the Company and supersede any prior representations or agreements whether written or oral. 
 You represent that you are not
bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter.

 If you agree with and accept the terms of this offer of employment, please sign below and return this letter to me. We are pleased to
have you join the Viamet team, and we look forward to our success together. 

 
			
	Very truly yours,
		
	By:	 	  

		 	Robert J. Schotzinger, M.D., Ph.D.
		 	President & CEO

  

	
	AGREED AND ACCEPTED BY:
	
	  

	Richard D. Katz, M.D., M.B.AEX-10.14

 Exhibit 10.14 

May     , 2016 
 Amir Tavakkol, Ph.D. 

40 East Shore Road 
 Mountain Lakes, NJ 07046 

Dear Amir, 
 It is my pleasure to extend the
following offer of employment to you on behalf of Viamet Pharmaceuticals Corp. (the “Company”) effective upon its conversion from Viamet Pharmaceuticals Holdings, LLC to a Delaware Corporation. The following is offered as part of your
compensation package: 
  

			
	Title:	  	Chief Development Officer
		
	Base Salary:	  	As determined by the Compensation Committee of the Board of Directors from time to time

 You will be eligible to receive an annual cash bonus as determined by the Company’s Board of Directors in
accordance with the Company’s performance-based bonus program. 
 Your employment with the Company is for no specified period and
constitutes “at-will” employment in that it can be terminated with or without cause, and with or without notice, at any time, at the option of either the Company or yourself, except as otherwise provided by law. The terms of this offer
letter, therefore, do not and are not intended to create either an express and/or implied contract of employment with the Company. Similarly, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any
compensation or grant you any benefit beyond the end of your employment with the Company. 
 This letter sets forth the terms of your
employment with the Company and supersede any prior representations or agreements whether written or oral. 
 You represent that you are not
bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter.

 If you agree with and accept the terms of this offer of employment, please sign below and return this letter to me. We are pleased to
have you join the Viamet team, and we look forward to our success together. 

 
			
	Very truly yours,
		
	By:	 	  

		 	Robert J. Schotzinger, M.D., Ph.D.
		 	President & CEO

  

	
	AGREED AND ACCEPTED BY:
	
	  

	Amir Tavakkol, Ph.D.EX-10.1

 Exhibit 10.1 

Execution Version 
 VOTING
AGREEMENT 
 This VOTING AGREEMENT, dated as of May 3, 2016 (this “Agreement”), among IMS Health Holdings, Inc., a
Delaware corporation (“IMS Health”), and the shareholders of Quintiles Transnational Holdings Inc., a North Carolina corporation (“Quintiles”), listed on Schedule A hereto (each, a
“Quintiles Shareholder” and, collectively, the “Quintiles Shareholders”). 
 RECITALS 

WHEREAS, concurrently herewith, IMS Health and Quintiles are entering into an Agreement and Plan of Merger (the “Merger
Agreement”; capitalized terms used but not defined in this Agreement shall have the meanings ascribed to them in the Merger Agreement), pursuant to which (and upon the terms and subject to the conditions set forth therein) IMS Health will
be merged with and into Quintiles, with Quintiles continuing as the surviving corporation in the merger on the terms and subject to the conditions of the Merger Agreement (the “Merger”); 

WHEREAS, each Quintiles Shareholder is the record and/or “beneficial owner” (within the meaning of Rule 13d-3 under the
Securities Exchange Act of 1934, as amended) of the number of common shares, par value $0.01 per share, of Quintiles (“Shares”) set forth opposite such Quintiles Shareholder’s name on Schedule A hereto
(with respect to each Quintiles Shareholder, the “Owned Shares”; the Owned Shares and any additional Shares or other voting securities of Quintiles of which such Quintiles Shareholder acquires record or beneficial ownership after
the date hereof, including by purchase, as a result of a stock dividend, stock split, recapitalization, combination, reclassification, exchange or change of such shares, or upon exercise or conversion of any securities, such Quintiles
Shareholder’s “Covered Shares”); 
 WHEREAS, as a condition and inducement to IMS Health’s willingness to enter
into the Merger Agreement and to proceed with the transactions contemplated thereby, including the Merger, IMS Health and the Quintiles Shareholders are entering into this Agreement; and 

WHEREAS, the Quintiles Shareholders acknowledge that IMS Health is entering into the Merger Agreement in reliance on the representations,
warranties, covenants and other agreements of the Quintiles Shareholders set forth in this Agreement and would not enter into the Merger Agreement if any Quintiles Shareholder did not enter into this Agreement. 

AGREEMENT 
 NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, IMS Health and the Quintiles Shareholders hereby agree as follows: 

1. Agreement to Vote. Prior to the Termination Date (as defined herein), each Quintiles Shareholder irrevocably and
unconditionally agrees that it shall, at any meeting 

 
of the shareholders of Quintiles (whether annual or special and whether or not an adjourned or postponed meeting), however called, or in connection with any action proposed to be taken by written
consent of the shareholders of Quintiles (a) when a meeting is held, appear at such meeting or otherwise cause the Covered Shares to be counted as present thereat for the purpose of establishing a quorum, and respond to each request by
Quintiles for written consent, if any, and (b) vote (or consent), or cause to be voted at such meeting (or validly execute and return and cause such consent to be granted with respect to), all Covered Shares (i) in favor of the adoption of
the Merger Agreement and any other matter that is required to facilitate the Merger and/or the other transactions contemplated by the Merger Agreement, including the Governance Matters, and (ii) against (A) any Acquisition Proposal with
respect to Quintiles (a “Quintiles Acquisition Proposal”), (B) any other action, agreement or proposal that could reasonably be expected to impede, interfere with, delay, postpone, frustrate, prevent, nullify or adversely
affect the Merger or any of the transactions contemplated by the Merger Agreement or this Agreement or change in any manner the voting rights of any class of the capital stock of Quintiles, (C) any change in the present capitalization or dividend
policy of Quintiles or any amendment or other change to Quintiles’s articles of incorporation or bylaws, except the Governance Matters or if approved by IMS Health, and (D) any other change in Quintiles’s corporate structure or
business. In the event that such Quintiles Shareholder’s proxy has been granted to IMS Health pursuant to Section 2(a), such Quintiles Shareholder shall have no obligations under this Section 1 with respect to the meeting of the shareholders of
Quintiles for which such proxy has been granted. Except as explicitly set forth in this Section 1, nothing in this Agreement shall limit the right of each Quintiles Shareholder to vote (including by proxy or written consent, if applicable) in favor
of, against or abstain with respect to any matters presented to Quintiles’s shareholders. 
 2. Grant of Irrevocable Proxy;
Appointment of Proxy. 
 (a) EACH QUINTILES SHAREHOLDER HEREBY GRANTS TO, AND APPOINTS, IMS HEALTH AS SUCH QUINTILES SHAREHOLDER’S
IRREVOCABLE (UNTIL THE TERMINATION DATE) PROXY AND ATTORNEY-IN-FACT (WITH FULL POWER OF SUBSTITUTION) TO VOTE THE COVERED SHARES AS INDICATED IN SECTION 1. EACH QUINTILES SHAREHOLDER INTENDS THIS PROXY TO BE IRREVOCABLE (UNTIL THE TERMINATION DATE)
AND COUPLED WITH AN INTEREST AND WILL TAKE SUCH FURTHER ACTION OR EXECUTE SUCH OTHER INSTRUMENTS AS MAY BE NECESSARY TO EFFECTUATE THE INTENT OF THIS PROXY AND HEREBY REVOKES ANY PROXY PREVIOUSLY GRANTED BY SUCH QUINTILES SHAREHOLDER WITH RESPECT TO
THE COVERED SHARES (SUCH QUINTILES SHAREHOLDER REPRESENTING TO IMS HEALTH THAT ANY SUCH PROXY IS NOT IRREVOCABLE). 
 (b) It is hereby
agreed that IMS Health will use the proxy granted in Section 2(a) solely in accordance with applicable Law and will only vote the Covered Shares subject to such proxy with respect to the matters and in the manner specified in Section 1. 

(c) The proxy granted in Section 2(a) shall automatically terminate, and any underlying appointment shall automatically be revoked and
rescinded and of no force and effect, upon the Termination Date, in each case without any further action by any party. 

  
 2 

 3. No Inconsistent Agreements. Each Quintiles Shareholder hereby represents,
covenants and agrees that, except as contemplated by this Agreement, such Quintiles Shareholder (a) has not, except for the Amended and Restated Shareholders Agreement, dated as of February 5, 2015, by and among Quintiles and the Shareholders
(as defined therein) (the “Quintiles SHA”), entered into, and shall not enter into at any time prior to the Termination Date, any voting agreement or voting trust with respect to any Covered Shares and (b) has not granted, and
shall not grant at any time prior to the Termination Date, a proxy or power of attorney with respect to any Covered Shares, in either case, which is inconsistent with such Quintiles Shareholder’s obligations pursuant to this Agreement. 

4. Termination. This Agreement shall terminate upon the earliest of (a) the Effective Time, (b) the termination of the Merger
Agreement in accordance with its terms, (c) written notice of termination of this Agreement by IMS Health to the Quintiles Shareholders (d) the entry into any amendment or modification of the Merger Agreement without the prior written consent
of the Quintiles Shareholders or any waiver of any of Quintiles’s rights under the Merger Agreement, in each case, which (i) results in a change in the amount or form of the Merger Consideration, (ii) results in an extension of the Outside Date
or (iii) is materially adverse to any of the Quintiles Shareholders and (e) the date on which the Quintiles Board effects a Quintiles Adverse Recommendation Change (such earliest date being referred to herein as the “Termination
Date”); provided that the provisions set forth in this Section 4, Section 7 and Sections 11 to 29 shall survive the termination of this Agreement; provided further that any liability incurred by any party hereto as
a result of a breach of a term or condition of this Agreement prior to such termination shall survive the termination of this Agreement. 

5. Representations and Warranties. 

(a) Each Quintiles Shareholder, as to itself (severally and not jointly), hereby represents and warrants to IMS Health as follows: 

(i) Such Quintiles Shareholder is the record and/or beneficial owner of, and has good and valid title to, the Owned Shares, free and clear of
Liens other than as created by this Agreement. Such Quintiles Shareholder has voting power, power of disposition, sole power to demand appraisal or dissenter rights, if any, and sole power to agree to all of the matters set forth in this Agreement,
in each case with respect to all of such Owned Shares, with no limitations, qualifications or restrictions on such rights, subject to applicable federal securities laws and the terms of this Agreement, except (x) as set forth below in this Section
5(a)(i) with regard to the Quintiles SHA and (y) that each Quintiles Shareholder may be deemed to share voting power and power of disposition over the Owned Shares with certain of its affiliates. As of the date hereof, other than the Owned Shares,
such Quintiles Shareholder does not own beneficially or of record any (i) shares of 

  
 3 

 
capital stock or voting securities of Quintiles, (ii) securities of Quintiles convertible into or exchangeable for shares of capital stock or voting securities of Quintiles or (iii) options or
other rights to acquire from Quintiles any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting securities of Quintiles. Other than the Quintiles SHA and that certain Coordination
Agreement, dated as of May 14, 2013, by and among the Quintiles shareholders that are party thereto, as amended, the Owned Shares are not subject to any voting trust agreement or other Contract to which such Quintiles Shareholder is a party
restricting or otherwise relating to the voting or Transfer (as defined below) of the Owned Shares. Such Quintiles Shareholder has not appointed or granted any proxy or power of attorney that is still in effect with respect to any Owned Shares,
except as contemplated by this Agreement. 
 (ii) Such Quintiles Shareholder is duly organized, validly existing and, to the extent
applicable in good standing, under the laws of the jurisdiction of its formation and has all requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder. The execution, delivery and performance of
this Agreement by such Quintiles Shareholder, the performance by such Quintiles Shareholder of its obligations hereunder and the consummation by such Quintiles Shareholder of the transactions contemplated hereby have been duly and validly authorized
by such Quintiles Shareholder and no other actions or proceedings on the part of such Quintiles Shareholder are necessary to authorize the execution and delivery by such Quintiles Shareholder of this Agreement, the performance by such Quintiles
Shareholder of its obligations hereunder or the consummation by such Quintiles Shareholder of the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by such Quintiles Shareholder and, assuming due
authorization, execution and delivery by IMS Health, constitutes a legal, valid and binding obligation of such Quintiles Shareholder, enforceable against such Quintiles Shareholder in accordance with its terms, except as enforcement may be limited
by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity (regardless of whether considered in a proceeding in equity or at law). 

(iii) Except for the applicable requirements of the Exchange Act, (i) no filing with, and no permit, authorization, consent or approval
of, any Governmental Entity is necessary on the part of such Quintiles Shareholder for the execution, delivery and performance of this Agreement by such Quintiles Shareholder or the consummation by such Quintiles Shareholder of the transactions
contemplated hereby and (ii) neither the execution, delivery or performance of this Agreement by such Quintiles Shareholder nor the consummation by such Quintiles Shareholder of the transactions contemplated hereby nor compliance by such
Quintiles Shareholder with any of the provisions hereof shall (A) conflict with or violate any provision of the organizational documents of such Quintiles Shareholder, (B) result in any breach or violation of, or constitute a default (or
an event which, with notice or lapse of time or both, would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of a Lien on such property or asset of such
Quintiles Shareholder pursuant to, any Contract to which such Quintiles Shareholder is a party or by which such Quintiles Shareholder or any property or asset of such Quintiles Shareholder is bound or affected or

  
 4 

 
(C) violate any order, writ, injunction, decree, statute, rule or regulation applicable to such Quintiles Shareholder or any of such Quintiles Shareholder’s properties or assets,
except, in the case of clause (B) or (C), for breaches, violations or defaults that would not, individually or in the aggregate, materially impair the ability of such Quintiles Shareholder to perform its obligations hereunder. 

(iv) There is no action, suit, investigation, complaint or other proceeding pending against such Quintiles Shareholder or, to the knowledge
of such Quintiles Shareholder, any other Person or, to the knowledge of such Quintiles Shareholder, threatened against such Quintiles Shareholder or any other Person that restricts or prohibits (or, if successful, would restrict or prohibit) the
exercise by IMS Health of its rights under this Agreement or the performance by any party of its obligations under this Agreement. 
 (v)
No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by the Merger Agreement or this Agreement based upon arrangements made by or on behalf of
such Quintiles Shareholder. 
 (vi) Such Quintiles Shareholder understands and acknowledges that IMS Health is entering into the Merger
Agreement in reliance upon such Quintiles Shareholder’s execution and delivery of this Agreement and the representations and warranties of such Quintiles Shareholder contained herein. 

(b) IMS Health hereby represents and warrants to each Quintiles Shareholder as follows: 

(i) IMS Health is duly organized, validly existing and, to the extent applicable in good standing, under the laws of the jurisdiction of its
formation and has all requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder. The execution, delivery and performance of this Agreement by IMS Health, the performance by IMS Health of its
obligations hereunder and the consummation by IMS Health of the transactions contemplated hereby have been duly and validly authorized by IMS Health and no other actions or proceedings on the part of IMS Health are necessary to authorize the
execution and delivery by IMS Health of this Agreement, the performance by IMS Health of its obligations hereunder or the consummation by IMS Health of the transactions contemplated hereby. This Agreement has been duly and validly executed and
delivered by IMS Health and, assuming due authorization, execution and delivery by the Quintiles Shareholders, constitutes a legal, valid and binding obligation of IMS Health, enforceable against IMS Health in accordance with its terms, except as
enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity (regardless of whether considered in a proceeding in equity or
at law). 
 (ii) Except for the applicable requirements of the Exchange Act, (i) no filing with, and no permit, authorization, consent
or approval of, any Governmental 

  
 5 

 
Entity is necessary on the part of IMS Health for the execution, delivery and performance of this Agreement by IMS Health or the consummation by IMS Health of the transactions contemplated hereby
and (ii) neither the execution, delivery or performance of this Agreement by IMS Health nor the consummation by IMS Health of the transactions contemplated hereby nor compliance by IMS Health with any of the provisions hereof shall
(A) conflict with or violate, any provision of the organizational documents of IMS Health, (B) result in any breach or violation of, or constitute a default (or an event which, with notice or lapse of time or both, would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of a Lien on such property or asset of IMS Health pursuant to, any Contract to which IMS Health is a party or by which IMS
Health or any property or asset of IMS Health is bound or affected or (C) violate any order, writ, injunction, decree, statute, rule or regulation applicable to IMS Health or any of IMS Health’s properties or assets except, in the case of
clause (B) or (C), for breaches, violations or defaults that would not, individually or in the aggregate, materially impair the ability of IMS Health to perform its obligations hereunder. 

(iii) There is no action, suit, investigation, complaint or other proceeding pending against IMS Health or, to the knowledge of IMS Health,
any other Person or, to the knowledge of IMS Health, threatened against IMS Health or any other Person that restricts or prohibits (or, if successful, would restrict or prohibit) the exercise by any Quintiles Shareholder of its rights under this
Agreement or the performance by any party of its obligations under this Agreement. 
 6. Certain Covenants of Quintiles
Shareholder. Each Quintiles Shareholder, for itself (severally and not jointly), hereby covenants and agrees as follows: 
 (a)
Subject to Section 7, prior to the Termination Date, such Quintiles Shareholder shall not, and shall not authorize or permit any of its Subsidiaries or controlled affiliates, or authorized any of their respective directors, officers, employees,
consultants, financial advisors, accountants, legal counsel, investment bankers, and other agents, advisors and representatives, directly or indirectly, to: 

(i) solicit, initiate, endorse, encourage or facilitate the making by any Person (other than the other parties to the Merger Agreement) of
any Quintiles Acquisition Proposal; 
 (ii) other than to inform any Person of the existence of the provisions contained in this Section 6,
enter into, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any Person any information or data with respect to, or otherwise cooperate in any way with, any Quintiles Acquisition Proposal; 

(iii) execute or enter into any Contract constituting or relating to any Quintiles Acquisition Proposal, or approve or recommend or propose
to approve or recommend any Quintiles Acquisition Proposal or any Contract constituting or relating to any Quintiles Acquisition Proposal (or authorize or resolve to agree to do any of the foregoing actions); or 

(iv) make, or in any manner participate in a “solicitation” (as such term is used in the rules of the Securities and Exchange
Commission (the “SEC”)) of proxies or powers of attorney or similar rights to vote, or seek to advise or influence any Person with respect to the voting of the Shares intending to facilitate any Quintiles Acquisition Proposal or
cause shareholders of Quintiles not to vote to approve the Merger or any other transaction contemplated by the Merger Agreement, 

  
 6 

 provided that the provisions of this Section 6(a) shall only apply to a Quintiles Shareholder’s or its
Subsidiaries’ or controlled affiliates’ consultants, financial advisors, accountants, legal counsel, investment bankers, and other agents, advisors and representatives (each, a “Third Party”) to the extent such Third Party
is acting on behalf of, or was encouraged by, the Quintiles Shareholder or its Subsidiaries or controlled affiliates. 
 (b) Such Quintiles
Shareholder will immediately cease and cause to be terminated all existing discussions or negotiations with any Person conducted heretofore with respect to any of the matters described in Section 6(a) above. 

(c) Prior to the Termination Date, and except as contemplated hereby, such Quintiles Shareholder shall not, without the prior written consent
of IMS Health, (i) tender any Covered Shares into any tender or exchange offer, (ii) sell (constructively or otherwise), transfer, pledge, hypothecate, grant, encumber, assign or otherwise dispose of (other than to an affiliate of such
Quintiles Shareholder that agrees in writing to be bound by the terms hereof and that certain Shareholders Agreement, dated as of the date hereof, by and among Quintiles and certain shareholders party thereto) (collectively,
“Transfer”), or enter into any contract, option, agreement or other arrangement or understanding with respect to the Transfer of, any of the Covered Shares or beneficial ownership or voting power thereof or therein (including by
operation of law), (iii) grant any proxies or powers of attorney, deposit any Covered Shares into a voting trust or enter into a voting agreement with respect to any Covered Shares or (iv) knowingly take any action that would make any
representation or warranty of such Quintiles Shareholder contained herein untrue or incorrect or have the effect of preventing or disabling such Quintiles Shareholder from performing its obligations under this Agreement. Any Transfer in violation of
this provision shall be void. Such Quintiles Shareholder further agrees to authorize and request Quintiles to notify Quintiles’s transfer agent that there is a stop transfer order with respect to all of the Covered Shares and that this
Agreement places limits on the voting of the Covered Shares; provided, however, that any such stop transfer order shall terminate upon the Termination Date. 

(d) Prior to the Termination Date, in the event that such Quintiles Shareholder acquires record or beneficial ownership of, or the power to
vote or direct the voting of, any additional Shares or other voting interests with respect to Quintiles, such Shares or voting interests shall, without further action of the parties, be deemed Covered Shares and subject to the provisions of this
Agreement, and the number of Shares held by such Quintiles Shareholder set forth on Schedule A hereto will be deemed amended accordingly and such Shares or voting interests shall automatically become subject to the terms of this
Agreement. Such Quintiles Shareholder shall promptly notify Quintiles and IMS Health of any such event. 

  
 7 

 7. Quintiles Shareholder Capacity. This Agreement is being entered into by each
Quintiles Shareholder solely in its capacity as a shareholder of Quintiles, and nothing in this Agreement shall restrict or limit the ability of any Quintiles Shareholder who is a director or officer of Quintiles, or any Person who is a director or
officer of Quintiles who may be affiliated or associated with, or nominated by, any Quintiles Shareholder or any of its affiliates, from exercising his or her fiduciary duties as a director or officer of Quintiles or from otherwise taking any action
or inaction in his or her capacity as a director or officer of Quintiles to the extent specifically permitted by the Merger Agreement, or subject to his fiduciary duties to Quintiles, or as he may otherwise be required by Law, and no such exercise
of fiduciary duties or action or inaction taken in such capacity as a director or officer of Quintiles shall be deemed to constitute a breach of this Agreement. For the avoidance of doubt, nothing in this Section 7 is intended to limit the
obligations of Quintiles under the Merger Agreement. 
 8. Disclosure. Each Quintiles Shareholder hereby authorizes Quintiles and IMS
Health to publish and disclose in any announcement or disclosure required by the SEC and in the Joint Proxy Statement/Prospectus such Quintiles Shareholder’s identity and ownership of the Covered Shares and the nature of such Quintiles
Shareholder’s obligations under this Agreement, provided that Quintiles and IMS Health shall give each Quintiles Shareholder and its legal counsel a reasonable opportunity to review and comment on any such announcement or disclosure prior to
its being made public. Except as may be required by applicable Law, no press release or other public statements by any Quintiles Shareholder regarding this Agreement, the transactions contemplated hereby, the Merger Agreement or the transactions
thereby are permitted, other than press releases or other public statements that are not inconsistent with previous press releases, public disclosures or public statements made jointly by Quintiles and IMS Health. 

9. Further Assurances. From time to time, at the request of IMS Health and without further consideration, each Quintiles
Shareholder shall take such further action as may reasonably be deemed by IMS Health to be necessary or desirable to consummate and make effective the transactions contemplated by this Agreement. 

10. Non-Survival of Representations and Warranties. The representations and warranties of the Quintiles Shareholders contained
herein shall not survive the closing of the transactions contemplated hereby and by the Merger Agreement. 
 11. Expenses. All
costs and expenses incurred in connection with this Agreement and the obligations hereunder shall be paid by the party incurring such costs and expenses, whether or not the transactions contemplated by the Merger Agreement are consummated. 

12. Amendment and Modification. This Agreement may not be amended, modified or supplemented in any manner, whether by course of
conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each party and otherwise as expressly set forth herein. 

  
 8 

 13. Waiver. No failure or delay of any party in exercising any right or remedy
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further
exercise thereof or the exercise of any other right or power. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies which they would otherwise have hereunder. Any agreement on the
part of a party to any such waiver shall be valid only if set forth in a written instrument executed and delivered by a duly authorized officer on behalf of such party. 

14. Notices. All notices and other communications hereunder shall be in writing and shall be deemed duly given (a) on the date of
delivery if delivered personally, or if by facsimile or e-mail, upon written confirmation of receipt by facsimile, e-mail or otherwise, (b) on the first Business Day following the date of dispatch if delivered utilizing a next-day service by a
recognized next-day courier or (c) on the earlier of confirmed receipt or the fifth Business Day following the date of mailing if delivered by registered or certified mail, return receipt requested, postage prepaid. All notices hereunder shall
be delivered to the addresses set forth below, or pursuant to such other instructions as may be designated in writing by the party to receive such notice: 

(i) If to a Quintiles Shareholder, to the address set forth opposite such Quintiles Shareholder’s name on
Schedule A hereto. 
 (ii) If to IMS Health: 

IMS Health Holdings, Inc. 
 83
Wooster Heights Road 
 Danbury, Connecticut 06810 

Attn: General Counsel 

Fax: (203) 448-4690 

Email: buscon@imshealth.com 

with a copy (which shall not constitute notice) to: 

Weil, Gotshal & Manges LLP 

767 Fifth Avenue 
 New York, New
York 10153 
 Attention: Michael J. Aiello 

Attention: Matthew J. Gilroy 

Facsimile: (212) 310-8007 

E-mail: michael.aiello@weil.com 

E-mail: matthew.gilroy@weil.com 

15. Entire Agreement. This Agreement constitutes the entire agreement, and supersedes all prior written agreements, arrangements,
communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings among the parties with respect to the subject matter hereof. 

  
 9 

 16. No Third-Party Beneficiaries. Nothing in this Agreement, express or implied, is
intended to or shall confer upon any Person other than the parties and their respective successors and permitted assigns any legal or equitable right, benefit or remedy of any nature under or by reason of this Agreement. 

17. Governing Law. This Agreement and all disputes or controversies arising out of or relating to this Agreement or the
transactions contemplated hereby shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws
principles of the State of Delaware. 
 18. Submission to Jurisdiction. Each of the parties hereto irrevocably agrees that any
legal action or proceeding arising out of or relating to this Agreement brought by any party hereto or its Affiliates against any other party hereto or its Affiliates shall be brought and determined in the Court of Chancery of the State of Delaware
in and for New Castle County, Delaware, provided that if jurisdiction is not then available in the Court of Chancery of the State of Delaware in and for New Castle County, Delaware, then any such legal action or proceeding may be brought in any
federal court located in the State of Delaware or any other Delaware state court. Each of the parties hereto hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and
unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby. Each of the parties hereto agrees not to commence any action, suit or proceeding relating
thereto except in the courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Delaware as described herein. Each of the parties hereto
further agrees that notice as provided herein shall constitute sufficient service of process and the parties hereto further waive any argument that such service is insufficient. Each of the parties hereto hereby irrevocably and unconditionally
waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or relating to this Agreement, (a) any claim that it is not personally subject to the jurisdiction of the
courts in Delaware as described herein for any reason, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to
judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is
improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts. 
 19. Assignment;
Successors. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise, by any party without the prior written consent of
the other parties, and any such assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties and their
respective successors and assigns. 

  
 10 

 20. Enforcement. The parties agree that irreparable damage would occur in the event
that the parties hereto do not perform the provisions of this Agreement in accordance with its terms or otherwise breach such provisions. Accordingly, prior to any termination of this Agreement pursuant to Section 4, the parties acknowledge and
agree that each party shall be entitled to an injunction, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of
Delaware in and for New Castle County, Delaware, provided that if jurisdiction is not then available in the Court of Chancery of the State of Delaware in and for New Castle County, Delaware, then in any federal court located in the State of Delaware
or any other Delaware state court, this being in addition to any other remedy to which such party is entitled at law or in equity. Each of the parties hereby further waives (a) any defense in any action for specific performance that a remedy at
law would be adequate and (b) any requirement under any law to post security as a prerequisite to obtaining equitable relief. 
 21.
Severability. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this
Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable Law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in such
jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein. 

22. Waiver of Jury Trial. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY
ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 23.
Counterparts. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and
delivered to the other party. 
 24. Facsimile or .pdf Signature. This Agreement may be executed by facsimile or .pdf signature
and a facsimile or .pdf signature shall constitute an original for all purposes. 
 25. Confidentiality. Each Quintiles
Shareholder agrees (a) to hold any non-public information regarding this Agreement and the Merger in strict confidence and (b) except as required by Law or legal process not to divulge any such non-public information to any third Person; provided,
however, that each Quintiles Shareholder may disclose non-public information to its financial advisors, legal counsel and other representatives, in each case, so long as such Person is bound by a customary confidentiality agreement or otherwise
subject to comparable confidentiality obligations. 

  
 11 

 26. Interpretation. When a reference is made in this Agreement to a Section or Schedule
such reference shall be to a Section or Schedule of this Agreement unless otherwise indicated. The headings contained in this Agreement or in any Schedule are for convenience of reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Any capitalized terms used in any Schedule but not otherwise defined therein shall have the meaning as
defined in this Agreement. All Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth herein. The word “including” and words of similar import when used in this Agreement
will mean “including, without limitation,” unless otherwise specified. The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to the Agreement as a
whole and not to any particular provision in this Agreement. The term “or” is not exclusive. The word “will” shall be construed to have the same meaning and effect as the word “shall.” References to days mean calendar
days unless otherwise specified. 
 27. No Presumption Against Drafting Party. Each of the parties to this Agreement
acknowledges that each party to this Agreement has been represented by counsel in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly, any rule of law or any legal decision that would require
interpretation of any claimed ambiguities in this Agreement against the drafting party has no application and is expressly waived. 
 28.
Obligations of Quintiles Shareholders. Notwithstanding anything to the contrary in this Agreement, the representations, warranties, covenants and agreements of each Quintiles Shareholder are several and not joint and several, and in no
event shall any Quintiles Shareholder have any obligation or liability for any of the representations, warranties and covenants of any other Quintiles Shareholder. 

29. No Ownership Interest. Except as specifically provided herein, (a) all rights, ownership and economic benefits of and relating to a
Quintiles Shareholder’s Covered Shares shall remain vested in and belong to such Quintiles Shareholder and (b) IMS Health shall have no authority to exercise any power or authority to direct or control the voting or disposition of any Shares or
direct such Quintiles Shareholder in the performance of its duties or responsibilities as a shareholder of Quintiles other than the right to vote the Quintiles Shareholder’s Covered Shares as proxy upon the terms and subject to the conditions
of this Agreement. Nothing in this Agreement shall be interpreted as creating or forming a “group” with any other Person, including IMS Health, for purposes of Rule 13d-5(b)(1) of the Exchange Act or any other similar provision of
applicable law. 
 30. Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement shall apply to (i) restrict any
actions taken by (x) any third-party investment manager managing any investments of any Quintiles Shareholder or any of its affiliates 

  
 12 

 
who have discretionary authority with respect to such investments, or (y) any portfolio company, investment fund or pooled investment vehicle in which any Quintiles Shareholder or any of its
affiliates may directly or indirectly invest or (ii) any Shares acquired by any such investment manager exercising discretionary authority or any such portfolio company, investment fund or pooled investment vehicle. 

[The remainder of this page is intentionally left blank.] 

  
 13 

 IN WITNESS WHEREOF, the parties below have caused to be executed or executed this Agreement as of
the date first written above. 
  

					
	IMS HEALTH HOLDINGS, INC.
		
	By:	 	 /s/ Harvey Ashman

		 	Name:	 	Harvey Ashman
		 	Title:	 	 Senior Vice President & General

Counsel

  
 SIGNATURE
PAGE TO VOTING AGREEMENT 

 
					
	TPG Shareholders:
	
	TPG QUINTILES HOLDCO II, L.P.
	By:	 	TPG Advisors V, Inc., its general partner
		
	By:	 	 /s/ Clive Bode

		 	Name:	 	Clive Bode
		 	Title:	 	Vice President
	
	TPG QUINTILES HOLDCO III, L.P.
	By:	 	TPG Advisors V, Inc., its general partner
		
	By:	 	 /s/ Clive Bode

		 	Name:	 	Clive Bode
		 	Title:	 	Vice President

  
 SIGNATURE
PAGE TO VOTING AGREEMENT 

 SCHEDULE A 
  

							
	 Quintiles Shareholder
	  	 Address
	  	Owned Shares	 
	 TPG Quintiles Holdco II, L.P.
	  	 301 Commerce Street, Suite 3300
 Fort Worth,
Texas 76102
 Attention: General Counsel

Telephone: (817) 871 - 4000
 Fax: (817) 871 - 4001

Email: legaldept@tpg.com
  

with a copy (which shall not constitute notice) to:
  

Cleary Gottlieb Steen & Hamilton LLP
 One Liberty Plaza

New York, NY 10006
 Attention: Paul J. Shim, Esq.

Telephone: (212) 225 - 2000
 Fax: (212) 225 - 3999
	  	 	6,775,964	  
	 TPG Quintiles Holdco III, L.P.
	  	 301 Commerce Street, Suite 3300
 Fort Worth,
Texas 76102
 Attention: General Counsel

Telephone: (817) 871 - 4000
 Fax: (817) 871 - 4001

Email: legaldept@tpg.com
  

with a copy (which shall not constitute notice) to:
  

Cleary Gottlieb Steen & Hamilton LLP
 One Liberty Plaza

New York, NY 10006
 Attention: Paul J. Shim, Esq.

Telephone: (212) 225 - 2000
 Fax: (212) 225 - 3999
	  	 	354,570	  
		  		  	  
	  
	 
	 Total
	  		  	 	7,130,534

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}]]